Drug and Vaccine industry
R&D in the pharmaceutical industry
With Bruno Versaevel, we are investigating for several years the R&D processes in the pharmaceutical industry. In
we aim in particular at understanding how the latter may explain the distribution of profits across the innovators and the drug manufacturers - and ultimately the structure of the industry.
The vaccine industry is very peculiar in that, by contrast to a drug, a vaccine cannot be produced by simple imitation. Its production requires very specific equipment and is thus, as such, a risky investment. Another line of research we share with Bruno consists in studying the the impact of the industry structure upon the investment timing - and ultimately, the date at which drugs or vaccines become available.
Together with Richard Ruble, we wrote a contribution on that subject which has been published in IJIO in 2014:
- "Investment timing and vertical relationship" (See also the Slides)
Within this context where firms investment timing depends upon the nature of their competition, we are also investigating the question of innovation protection in
- "When should a winner take all, or pay some? Innovation and imitation incentives in a dynamic duopoly"
for which the slides are available
Mental Health and Pharmacology
In the process of taking part to various initiatives that aim at inter-disciplinary dialogue, I came to know several researchers in the filed of Mental Health, gathered around Catherine Belzung.
Together, we have been working on how to model mental disorders. This gave rise to the note in BBS:
- "Latent Variables and the Network Perspective: Commentary on Cramer and alii,"
which is joint with Catherine Belzung, Vincent Camus and Mael Lemoine.
With Catherine Belzung, we also came up with a formal model of the HPA-Axis, which is at the core of stress regulation:
- "The Design of New Antidepressants: can Formal Models help? A First Attempt using a Model of the Hippocampal Control over the HPA-axis based on a Review from the Literature"
According the WHO, major depression is about to become globally the most prevalent health disorder. Equipped with a better knowledge of how mental disorders are actually understood in the broad field of neuroscience, I hope to be able to come up with more relevant models to tackle this very serious public health problem.